Wednesday, May 18, 2022

Catabasis Pharmaceuticals, Inc. (CATB) Stock Price Trending Upwards Following Developments

Catabasis Pharmaceuticals, Inc. (CATB) stock prices enjoyed an 8.48% uptrend as of market close on April 19th, 2021, settling into a price of USD$2.43 per share. Subsequent pre-market fluctuations saw CATB stock prices climb further to hit UDS$2.44, a 0.41% increase.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


CATB Acquires Quellis

In January 2021, Quellis Biosciences Inc. was acquired by CATB in an agreement wherein a combination of CATB’s common and Series X Preferred Stock were traded for all of Quellis’ outstanding equity interests. Quellis is a privately-held biopharmaceutical company that focuses on discovering new molecules that are best-in-class and could treat rare diseases.

CATB Raises Capital


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Concurrently, CATB started a PIPE (private investment in public equity), which offers shares of its Series X Preferred Stock to current and prospective investors. The expected proceeds from this move come out to USD$110 million, with each Series X Preferred Stock being valued at USD$3,093. Each Preferred Stock share can be converted into 1,000 shares of CATB common stock, each of which will be priced at USD$3.09.

Allocation of Generated Capital

The generated capital will be put towards funding the completion of CATB’s IND-enabling studies, alongside Phase 1a and Phase 1b/2 clinical trials of its lead program QLS-215, which aims to treat angioedema. With operations expected to run through to 2023, CATB anticipates cash proceeds in the vicinity of USD$150 million being generated.

CATB Stock Situation

Following the acquisition of Quellis and the closing of the private placement, CATB had roughly 23.4 million shares of its common stock and roughly 86,000 shares of its Series X Preferred Stock outstanding. Should the Preferred Stock shares be converted into common stock shares, CABT will have roughly 109.5 million shares outstanding.

2020 Financial Reports

In the release of their financial reports for the year ended 30th December 2021, CATB reported USD$44.9 million in cash, cash equivalents and short-term investments. With the USD$104 million generated from the private placement after the deduction of costs associated with the offering, CATB finds itself with enough cash to fund its operation plan as it stands through to 2023.

Investing in R&D

With USD$5.7 million going towards research and development in Q4 2020, CATB is shown to be gradually investing more money in their R&D. This is indicated by the increase in Q4 2020 from the USD$4.3 million that was invested in R&D in Q4 2019. 2020 reported R&D costs for the whole year at USD$25.6 million, while costs for 2019 were USD$18.3 million.

CATB’s Future Outlook

With the acquisition of Quellis and the strong financial foothold offered by the private placement, CATB finds itself in a prime position to leverage its resources to increase shareholder value. How their clinical trials and product development proceed will determine the long-term future of the company.

Latest news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

Related news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam